Rotating Pazopanib and Everolimus to Avoid Resistance
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
In this study will be examined whether alternating treatment between two classes of drugs
(TKI's and m-TOR inhibitors) postpones or prevents drug resistance in patients with renal
cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Netherlands Working Group on Immunotherapy of Oncology